News

Enterome Presents Positive Phase 2 Interim Results In Relapsed/Refractory Indolent Non-Hodgkin Lymphoma After EO2463 Oncomimicstm Immunotherapy Treatment At ICML
(12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2) <li /> EO ...